Comparison of efficacy and safety after administering high potency statin to high risk patients: Rosuvastatin 10 mg versus atorvastatin 20 mg

Korean Circulation Journal

Volumn 37, Issue 4, 2007, Pages 154-160

  Kyeong, Ho Yun ^a   Park, Hyun Young ^a   Choi, Jun Ho ^a   Song, Mi Jin ^a   Eun, Mi Park ^a   Yun, Kyung Kim ^a   Sang, Jae Rhee ^a   Eun, Mi Lee ^a   Lee, Je ^a   Nam, Jin Yoo ^a   Kim, Nam Ho ^a   Seok, Kyu Oh ^a   Jeong, Jin Won ^a  

^a Wonkwang University Hospital   (South Korea)

Author keywords

Cholesterol; Guideline; Hydroxylmethyglutaryl CoA reductase inhibitors

Indexed keywords

ATORVASTATIN; LOW DENSITY LIPOPROTEIN; ROSUVASTATIN;

ABDOMINAL PAIN; ACUTE CORONARY SYNDROME; ACUTE DISEASE; ADULT; AGED; ARTICLE; BLEEDING DISORDER; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG EFFICACY; DRUG FATALITY; DRUG POTENCY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEADACHE; HIGH RISK PATIENT; HUMAN; LIPID BLOOD LEVEL; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MYALGIA; PATIENT COMPLIANCE; RHABDOMYOLYSIS; SIDE EFFECT; STROKE; UNSPECIFIED SIDE EFFECT;

EID: 34249779553     PISSN: 17385520     EISSN: 17385555     Source Type: Journal    
DOI: 10.4070/kcj.2007.37.4.154     Document Type: Article

References (27)

1. Sacandinavian Simvastatin Survival Study (4S). Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease. Lancet 1994; 344: 1383-9.
2. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia: west of Scotland cornary prevention study group. N Engl J Med 1995; 333: 1301-7.
3. Kim CJ. In the shadow of the statin festival. Korean Circ J 2006; 36: 77-83.
4. Long-Term Intervention with Pravastatin in Ischemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients of coronary heart disease and a board range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
5. Jukema JW, Bruschke AV, van Boven AJ, et al. Effects of lipid lowering by pravastatin on progression and regression of coronary artery disease in symptomatic men with normal to moderately elevated serum cholesterol levels. Circulation 1995; 91: 2528-40.
6. Nissen SE, Tuzcu EM, Schoenhagen P, et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 2004; 291: 1071-80.
7. Okazaki S, Yokoyama T, Miyauchi K, et al. Early statin treatment in patients with acute coronary syndrome: demonstration of the beneficial effect on atherosclerotic lesions by serial volumetric intravascular ultrasound analysis during half a year after coronary event. Circulation 2004; 110: 1061-8.
8. Yokoi H, Nobuyoshi M, Mitsudo K, Kawaguchi A, Yamamoto A. Three-year follow-up results of angiographic intervention trial using an HMG-CoA reductase inhibitor to evaluate retardation of obstructive multiple atheroma (ATHEROMA) study. Circ J 2005; 69: 875-83.
9. Nissen SE, Nicholls SJ, Sipahi I, et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. JAMA 2006; 295: 1556-65.
10. Kim SH, Park JS, Zo JH, Kim MA, Kim HS. Treatment gap in the management of hypercholesterolemia in Korea: return on expenditure achieved for lipid therapy (REALITY). Korean Circ J 2006; 36: 593-9.
11. Pearson TA, Peters TD. The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patients. Am J Cardiol 1997; 80: 45H-52H.
12. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP). Arch Intern Med 2000; 160: 459-67.
13. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am J Cardiol 2003; 92: 152-60.
14. Friedewald WT, Levy RI, Frederickson DS. Estimation of concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
15. West of Scotland Coroanry Prevention Study. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97: 1440-5.
16. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002; 360: 1623-30.
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
18. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495-504.
19. Larosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005; 352: 1425-35.
20. de Lemos JA, Blazing MA, Wiviott SD, et al. Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004; 292: 1307-16.
21. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227-39.
22. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/ SCAI 2005 guideline update for percutaneous coronary intervention. J Am Coll Cardiol 2006; 47: e1-121.
23. Kostner GM, Gavish D, Leopold B, Bolzano K, Weintraub MS, Breslow JL. HMG-CoA reductase inhibitors lower LDL cholesterol without reducing Lp (a) levels. Circulation 1989; 80: 1313-9.
24. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
25. Tekin A, Tekin G, Guzelsoy D, et al. Effects of atorvastatin (10 mg) on hemostatic and inflammatory parameters in hyperlipidemic patients with angiographically ptoven coronary artery disease. Am J Cardiol 2004; 94: 206-9.
26. Jones P, Kafonek S, Laurora I, Hunninghake D. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 1998; 81: 582-7.
27. Schneck DW, Knopp RH, Ballantyne CM, McPherson R, Chitra RR, Simonson SG. Comparative effects of rosuvastatin and atorvastatin across their dose ranges in patients with hypercholesterolemia and without active arterial disease. Am J Cardiol 2003; 91: 33-41.